Literature DB >> 28792760

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.

Jin-Yi Zhu1, Rebecca A Cuellar2, Norbert Berndt1, Hee Eun Lee1, Sanne H Olesen1, Mathew P Martin1, Jeffrey T Jensen3, Gunda I Georg2, Ernst Schönbrunn1.   

Abstract

Members of the Wee family of kinases negatively regulate the cell cycle via phosphorylation of CDK1 and are considered potential drug targets. Herein, we investigated the structure-function relationship of human Wee1, Wee2, and Myt1 (PKMYT1). Purified recombinant full-length proteins and kinase domain constructs differed substantially in phosphorylation states and catalytic competency, suggesting complex mechanisms of activation. A series of crystal structures reveal unique features that distinguish Wee1 and Wee2 from Myt1 and establish the structural basis of differential inhibition by the widely used Wee1 inhibitor MK-1775. Kinome profiling and cellular studies demonstrate that, in addition to Wee1 and Wee2, MK-1775 is an equally potent inhibitor of the polo-like kinase PLK1. Several previously unrecognized inhibitors of Wee kinases were discovered and characterized. Combined, the data provide a comprehensive view on the catalytic and structural properties of Wee kinases and a framework for the rational design of novel inhibitors thereof.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28792760      PMCID: PMC6200136          DOI: 10.1021/acs.jmedchem.7b00996

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  47 in total

1.  Identification and characterization of human Wee1B, a new member of the Wee1 family of Cdk-inhibitory kinases.

Authors:  M Nakanishi; H Ando; N Watanabe; K Kitamura; K Ito; H Okayama; T Miyamoto; T Agui; M Sasaki
Journal:  Genes Cells       Date:  2000-10       Impact factor: 1.891

Review 2.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

3.  In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

Authors:  R L Panek; G H Lu; S R Klutchko; B L Batley; T K Dahring; J M Hamby; H Hallak; A M Doherty; J A Keiser
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

4.  Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog.

Authors:  P Russell; P Nurse
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

5.  Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation.

Authors:  Christopher J Squire; James M Dickson; Ivan Ivanovic; Edward N Baker
Journal:  Structure       Date:  2005-04       Impact factor: 5.006

6.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Authors:  Khanh Do; Deborah Wilsker; Jiuping Ji; Jennifer Zlott; Tomoko Freshwater; Robert J Kinders; Jerry Collins; Alice P Chen; James H Doroshow; Shivaani Kummar
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

7.  PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Authors:  Ankita Jhuraney; Nicholas T Woods; Gabriela Wright; Lily Rix; Fumi Kinose; Jodi L Kroeger; Elizabeth Remily-Wood; W Douglas Cress; John M Koomen; Stephen G Brantley; Jhanelle E Gray; Eric B Haura; Uwe Rix; Alvaro N Monteiro
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Discovery of Diverse Small-Molecule Inhibitors of Mammalian Sterile20-like Kinase 3 (MST3).

Authors:  Sanne H Olesen; Jin-Yi Zhu; Mathew P Martin; Ernst Schönbrunn
Journal:  ChemMedChem       Date:  2016-05-02       Impact factor: 3.466

Review 10.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  19 in total

1.  Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.

Authors:  Christopher J Matheson; Kimberly A Casalvieri; Donald S Backos; Philip Reigan
Journal:  ChemMedChem       Date:  2018-07-11       Impact factor: 3.466

2.  ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

Authors:  Mark C de Gooijer; Levi C M Buil; Jos H Beijnen; Olaf van Tellingen
Journal:  Invest New Drugs       Date:  2017-11-17       Impact factor: 3.850

3.  Homozygous missense mutation Arg207Cys in the WEE2 gene causes female infertility and fertilization failure.

Authors:  Xiaoyu Yang; Li Shu; Lingbo Cai; Xueping Sun; Yugui Cui; Jiayin Liu
Journal:  J Assist Reprod Genet       Date:  2019-03-02       Impact factor: 3.412

4.  Identification and Screening of Selective WEE2 Inhibitors to Develop Non-Hormonal Contraceptives that Specifically Target Meiosis.

Authors:  Carol B Hanna; Shan Yao; Mat Martin; Ernst Schönbrunn; Gunda I Georg; Jeffrey T Jensen; Rebecca A D Cuellar
Journal:  ChemistrySelect       Date:  2019-12-05       Impact factor: 2.109

5.  mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers.

Authors:  Fuxia Li; Ensong Guo; Jia Huang; Funian Lu; Bin Yang; Rourou Xiao; Chen Liu; Xue Wu; Yu Fu; Zizhuo Wang; Shaohua Peng; Yu Lei; Zhongzhen Guo; Lei Li; Ling Xi; Chaoyang Sun; Si Liu; Gang Chen
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

6.  Multimodal platform for assessing drug distribution and response in clinical trials.

Authors:  Begoña G C Lopez; Ishwar N Kohale; Ziming Du; Ilya Korsunsky; Walid M Abdelmoula; Yang Dai; Sylwia A Stopka; Giorgio Gaglia; Elizabeth C Randall; Michael S Regan; Sankha S Basu; Amanda R Clark; Bianca-Maria Marin; Ann C Mladek; Danielle M Burgenske; Jeffrey N Agar; Jeffrey G Supko; Stuart A Grossman; Louis B Nabors; Soumya Raychaudhuri; Keith L Ligon; Patrick Y Wen; Brian Alexander; Eudocia Q Lee; Sandro Santagata; Jann Sarkaria; Forest M White; Nathalie Y R Agar
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 13.029

7.  Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.

Authors:  Naoko Takebe; Abdul Rafeh Naqash; Geraldine O'Sullivan Coyne; Shivaani Kummar; Khanh Do; Ashley Bruns; Lamin Juwara; Jennifer Zlott; Larry Rubinstein; Richard Piekarz; Elad Sharon; Howard Streicher; Arjun Mittra; Sarah B Miller; Jiuping Ji; Deborah Wilsker; Robert J Kinders; Ralph E Parchment; Li Chen; Ting-Chia Chang; Biswajit Das; Ganesh Mugundu; James H Doroshow; Alice P Chen
Journal:  Clin Cancer Res       Date:  2021-04-16       Impact factor: 13.801

8.  Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma.

Authors:  Qingyi Zhang; Xuan Zhao; Chaoqi Zhang; Wei Wang; Feng Li; Donglei Liu; Kai Wu; Dengyan Zhu; Shasha Liu; Chunyi Shen; Xin Yuan; Kai Zhang; Yang Yang; Yi Zhang; Song Zhao
Journal:  Cancer Manag Res       Date:  2019-08-19       Impact factor: 3.989

9.  Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.

Authors:  Angela Flavia Serpico; Giuseppe D'Alterio; Cinzia Vetrei; Rosa Della Monica; Luca Nardella; Roberta Visconti; Domenico Grieco
Journal:  Cancers (Basel)       Date:  2019-06-13       Impact factor: 6.639

Review 10.  Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.

Authors:  Matthias Schmidt; Alexander Rohe; Charlott Platzer; Abdulkarim Najjar; Frank Erdmann; Wolfgang Sippl
Journal:  Molecules       Date:  2017-11-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.